TABLE 1.
Characteristics of study participants stratified by self‐reported race
|
All patients (N = 3492) |
White patients (N = 3019) |
Black patients (N = 365) |
p value a | |
|---|---|---|---|---|
| Age (years) at first treatment, Mean ± SD | 59.2 ± 12.6 | 59.6 ± 12.4 | 56.7 ± 12.5 | 1.82 × 10−5 |
| Age categorical, N (%) | 0.003 | |||
| <55 | 1166 (33.4) | 966 (32.0) | 144 (39.5) | |
| 55 to <65 | 1059 (30.3) | 920 (30.5) | 118 (32.3) | |
| 65 to <75 | 905 (25.9) | 809 (26.8) | 77 (21.1) | |
| ≥75 | 362 (10.4) | 324 (10.7) | 26 (7.1) | |
| Sex, N (%) | 3.68 × 10−8 | |||
| Female | 2046 (58.6) | 1713 (56.7) | 262 (71.8) | |
| Male | 1466 (41.4) | 1306 (43.3) | 103 (28.2) | |
| Taxane type (%) | 0.008 | |||
| Docetaxel | 838 (24.0) | 689 (22.8) | 106 (29.0) | |
| Paclitaxel | 2654 (76.0) | 2330 (77.2) | 259 (71.0) | |
| Mean taxane treatment duration (months) ± SD | 2.9 ± 4.7 | 2.9 ± 4.9 | 2.7 ± 3.2 | 0.380 |
| BMI, Mean ± SD | 28.2 ± 6.7 | 28.1 ± 6.4 | 30.2 ± 8.3 | 4.59 × 10−9 |
| BMI categorical, N (%) | 2.23 × 10−8 | |||
| <18.5 | 113 (3.2) | 94 (3.1) | 13 (3.6) | |
| 18.5 to <25 | 1093 (31.3) | 958 (31.7) | 89 (24.4) | |
| 25 to <30 | 1112 (31.8) | 987 (32.7) | 96 (26.3) | |
| 30 to <35 | 977 (28.0) | 830 (27.5) | 124 (34.0) | |
| ≥40 | 197 (5.7) | 150 (5.0) | 43 (11.8) | |
| Ever smoke, N (%) | 1587 (45.4) | 1415 (46.9) | 141 (38.6) | 0.006 |
| Cancer type, N (%) b | 4.16 × 10−8 | |||
| Breast | 1149 (32.9) | 930 (30.8) | 173 (47.4) | |
| Head & Neck | 789 (22.6) | 710 (23.5) | 53 (14.5) | |
| Lung & Other Respiratory | 624 (17.9) | 559 (18.5) | 50 (13.7) | |
| Female Genital & Reproductive | 215 (6.2) | 181 (6.0) | 27 (7.4) | |
| Gastrointestinal | 185 (5.3) | 165 (5.5) | 18 (4.9) | |
| Unknown | 135 (3.9) | 114 (3.8) | 17 (4.7) | |
| Cancer stage, N (%) c | 0.0407 | |||
| I | 398 (11.4) | 328 (10.9) | 56 (15.3) | |
| II | 472 (13.5) | 405 (13.4) | 46 (12.6) | |
| III | 484 (13.9) | 415 (13.7) | 55 (15.1) | |
| IV | 788 (22.6) | 698 (23.1) | 66 (18.1) | |
| Unknown | 1350 (38.7) | 1173 (38.9) | 142 (38.9) | |
| Mean baseline neutrophil count (103/µL) ± SD | 5.6 ± 3.0 | 5.7 ± 3.0 | 5.1 ± 3.1 | 0.001 |
| Mean treatment dose (mg/m2) ± SD | 81.0 ± 45.0 | 80.5 ± 45.8 | 84.7 ± 40.1 | 0.094 |
| Prophylactic GCSF, N (%) | 271 (7.8) | 220 (7.3) | 42 (11.5) | 0.004 |
| Co‐chemotherapy, N (%) | 777 (22.3) | 654 (21.7) | 101 (27.7) | 0.009 |
| Platinum, N (%) | 687 (19.7) | 583 (19.3) | 85 (23.3) | 0.071 |
| Prior chemotherapy, N (%) | 3270 (93.6) | 2833 (93.8) | 339 (92.9) | 0.474 |
| Platinum, N (%) | 2466 (70.6) | 2175 (72.0) | 216 (59.2) | 3.42 × 10−7 |
| Prior radiotherapy, N (%) | 833 (23.9) | 755 (25.0) | 69 (18.9) | 0.010 |
a
p values derived from Pearson's χ 2 tests for independence for the categorical variables and Student t tests for the continuous variables comparing self‐reported race.
b
Top five cancer types are listed. Cancer types were determined using most recent diagnosis code to start of taxane treatment. Patients without diagnosis codes were grouped into “Unknown.”
c
Cancer stage was determined from VUMC NAACCR data, which was only available for patients diagnosed at VUMC.